Jiangsu Cowin Biotech Co., Ltd.SSE: 688426

Announcement on Expected Loss in Performance for 2025

Jan 30, 2026 · Issued by Jiangsu Cowin Biotech Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Jan 30, 2026

On 6ix: 6ix.com/news/announcement-on-expected-loss-in-performance-for-2025-163

Announcement on Expected Loss in Performance for 2025

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Jiangsu Cowin Biotech Co., Ltd. on 6ix

Earlier from Jiangsu Cowin Biotech

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026Jan 29
Announcement on Shareholding Reduction Plan of Partial Directors and Senior Management MembersJan 15
Notice on Convening the 1st Extraordinary General Meeting in 2026Jan 13
Announcement on Listing and Circulation of Shares Subject to Lock-up Released from Stock Option Exercises Granted Prior to the Initial Public OfferingDec 15, 2025
Report for Q3 2025Oct 31, 2025

Later from Jiangsu Cowin Biotech

Announcement on Retirement and Resignation of Internal Audit HeadsFeb 3
Announcement on Change of Sponsor Representative for Continuous SupervisionFeb 25
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Announcement on Voluntary Disclosure of the Receipt of Class III Medical Device Registration Certificates for Nine Respiratory Pathogen Nucleic Acid Detection Kits (Fluorescent PCR Method)Mar 5
Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public OfferingApr 17

All Jiangsu Cowin Biotech news releases

Follow Jiangsu Cowin Biotech into a list and get an email when it puts out news.

Follow Jiangsu Cowin Biotech